Business Description
InMed Pharmaceuticals Inc
NAICS : 325411
SIC : 3741
ISIN : CA4576371062
Description
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 8.17 | |||||
| Equity-to-Asset | 0.84 | |||||
| Debt-to-Equity | 0.09 | |||||
| Debt-to-EBITDA | -0.18 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | -9.45 | |||||
| Beneish M-Score | -0.34 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 57.8 | |||||
| 3-Year EPS without NRI Growth Rate | 57.8 | |||||
| 3-Year FCF Growth Rate | 55.9 | |||||
| 3-Year Book Growth Rate | -49.5 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 29.87 | |||||
| 9-Day RSI | 35.6 | |||||
| 14-Day RSI | 38.97 | |||||
| 6-1 Month Momentum % | -69.84 | |||||
| 12-1 Month Momentum % | -73.86 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 7.03 | |||||
| Quick Ratio | 6.59 | |||||
| Cash Ratio | 5.68 | |||||
| Days Inventory | 139.09 | |||||
| Days Sales Outstanding | 13.98 | |||||
| Days Payable | 59.17 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -151.7 | |||||
| Shareholder Yield % | -312.87 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 38.42 | |||||
| Operating Margin % | -127.47 | |||||
| Net Margin % | -115.75 | |||||
| FCF Margin % | -115.86 | |||||
| ROE % | -51.92 | |||||
| ROA % | -44.15 | |||||
| ROIC % | -172.39 | |||||
| ROC (Joel Greenblatt) % | -465.58 | |||||
| ROCE % | -56.19 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 0.21 | |||||
| PB Ratio | 0.13 | |||||
| Price-to-Tangible-Book | 0.16 | |||||
| EV-to-EBIT | 0.93 | |||||
| EV-to-EBITDA | 1.02 | |||||
| EV-to-Revenue | -1.19 | |||||
| EV-to-Forward-Revenue | 0.01 | |||||
| EV-to-FCF | 1.03 | |||||
| Price-to-Net-Current-Asset-Value | 0.18 | |||||
| Price-to-Net-Cash | 0.24 | |||||
| Earnings Yield (Greenblatt) % | 107.53 | |||||
| FCF Yield % | -345.15 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
InMed Pharmaceuticals Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 5.081 | ||
| EPS (TTM) (€) | -1.188 | ||
| Beta | -0.36 | ||
| Volatility % | 64.8 | ||
| 14-Day RSI | 38.97 | ||
| 14-Day ATR (€) | 0.017783 | ||
| 20-Day SMA (€) | 0.2876 | ||
| 12-1 Month Momentum % | -73.86 | ||
| 52-Week Range (€) | 0.235 - 1.53 | ||
| Shares Outstanding (Mil) | 6.06 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
InMed Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
InMed Pharmaceuticals Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
InMed Pharmaceuticals Inc Frequently Asked Questions
What is InMed Pharmaceuticals Inc(FRA:MWG0)'s stock price today?
The current price of FRA:MWG0 is €0.24. The 52 week high of FRA:MWG0 is €1.53 and 52 week low is €0.24.
When is next earnings date of InMed Pharmaceuticals Inc(FRA:MWG0)?
The next earnings date of InMed Pharmaceuticals Inc(FRA:MWG0) is 2024-05-15 Est..
Does InMed Pharmaceuticals Inc(FRA:MWG0) pay dividends? If so, how much?
InMed Pharmaceuticals Inc(FRA:MWG0) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers